Trial · NCT01950234
Outcomes22
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Patients Exhibiting a 20% Worsening in T25FW at 36 Months | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Menstrual Changes [Female] | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: DEXA Scans | Month 36 | units on a scale | MEAN | |
| SECONDARY | Safety and Tolerability of ACTH: Bruising | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Swelling Ankles | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Hair Loss | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Acne | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Insomnia | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Mood Change | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: GI Upset | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Fatigue | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Unpleasant Taste | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Blurred Vision | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Moon Facies | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Skin Thinning | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Hirsuitism | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Bruising | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Ankle Swelling | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Hair Loss | Month 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Safety and Tolerability of ACTH: Cataracts | Month 36 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01950234/outcomes